Upcoming Login Downtime
We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.
For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Oct 26, 2023
Product Development
CTAD Roundup: Subcutaneous version of Leqembi moves toward submission
Plus: Biogen reports early signs of efficacy with anti-tau ASO and Grifol’s anti-amyloid vaccine meets safety, immunogenicity endpoints
BioCentury | May 5, 2022
Regulation
May 4 Quick Takes: FDA clears Fujirebio’s Alzheimer’s diagnostic
Plus Jazz licenses sleep disorder therapy from Sumitomo and updates from Apnimed, Phathom, AZ, Kezar
BioCentury | Nov 10, 2021
Product Development
Genentech pours cold water on blood test for Alzheimer’s screening
Argues plasma Aβ42/40 falls short as a method for identifying patients for clinical trials
BioCentury | May 4, 2018
Clinical News
Merck's verubecestat reduces beta amyloid levels but fails to improve cognition, function
Items per page:
1 - 10 of 27